Facilities

Pic:getty/stanislawpytel

Emmes launches cell and gene therapy center

By Rachel Arthur

Emmes has announced the creation of a dedicated center for cell and gene therapy research: which will focus on supporting clinical trials for the Clinical Research Organization’s (CRO) clients.

Pic:getty/markrubens

BioNTech acquires GMP manufacturing site in Singapore

By Rachel Arthur

BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.

Melbourne wants to become an mRNA hub, with investments from both BioNTech & Moderna. Pic: getty/walterbibikow

BioNTech to build mRNA center in Australia

By Rachel Arthur

BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.

Pic:getty/markrubens

WuXi Biologics to build CRDMO center in Singapore

By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

© GettyImages/acilo

Kite secures third approved cell therapy indication in Europe

By Jane Byrne

The European Commission (EC) has approved Kite’s CAR T-cell therapy, Yescarta, (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

Pic:getty/omersukrugoksu

Lilly invests $2.1bn in new Indiana manufacturing sites

By Rachel Arthur

Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.

Pic:getty/chaluk

Matica Bio opens new Texas cell and gene therapy facility

By Rachel Arthur

CDMO Matica Bio has opened a new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.